CALMARE® Pain Therapy Treatment
Project Number:
Patent Numbers:
US patented
FDA 510(k) clearance for US sales
European Union Medical Device CE approved as an electronic-analgesic apparatus
The technology is from the research of Professor Giuseppe Marineo, a researcher and bioengineer, and the founder and manager of Delta Research & Development. Delta R&D, formed in May 1998, is a Medical Bioengineering Research Centre affiliated with Tor Vergata University of Rome in Italy.
The pain therapy technology is a non-invasive method for rapid treatment of high-intensity oncologic, neuropathic, and drug-resistant pain through a biophysical rather than a biochemical manner. The method incorporates electromedical equipment for electronic nerve stimulation, and uses the nerve fiber as a passive means to convey a message of normality to the central nervous system (CNS) by a procedure defined as scrambling or tricking of information, which then enables the CNS to modify the reflex adaptive responses - referred to as TEMPR - Transcutaneous Electrical Modulation Pain Reprocessor. It has been successfully used on over 3,000 patients in Europe.
The non-invasive MC-5A, using Scrambler Therapy® technology, is a multiprocessor apparatus able to simultaneously treat multiple pain areas in the individual. The patient experiences longer "no pain" periods after each successive treatment.
The global pain management market is estimated to reach $60 billion by 2015. Potential market opportunities include hospitals, nursing homes and hospices, cancer treatment centers, and pain management centers.

For more information please contact:

Conrad F. Mir
President, CEO and Director
Calmare Therapeutics Incorporated
This email address is protected. Javascript must be enabled to view it.
Tel: 973.798.8882